Entacapone protects from angiotensin II-induced inflammation and renal injury

Objectives and design Angiotensin II (Ang II)-induced renal damage is associated with perivascular inflammation and increased oxidative stress. We tested the hypothesis whether entacapone, a catechol-O-methyltransferase (COMT) inhibitor exerting antioxidative and anti-inflammatory properties, protects against the Ang II-induced inflammatory response and end-organ damage. Methods Samples from double-transgenic rats harbouring human renin and human angiotensinogen genes (dTGR) and normotensive Sprague–Dawley rats (SD) were assessed by light microscopy, immunohistochemistry, reverse transcriptase-polymerase chain reaction (RT-PCR), and high pressure liquid chromatography. The effects of entacapone treatment for 3 weeks were examined in dTGR and SD. Results Entacapone completely prevented cardiovascular mortality and decreased albuminuria by 85% in dTGR. Entacapone ameliorated Ang II-induced vascular and glomerular damage, leucocyte infiltration, and intercellular adhesion molecule-1 (ICAM-1) overexpression in the kidneys. Serum 8-isoprostane concentration, as well as renal nitrotyrosine and 8-hydroxydeoxyguanosine expressions, all markers of oxidative stress, were markedly increased in dTGR and normalized by entacapone. Entacapone also decreased p22phox mRNA expression in the kidney. COMT expression was increased by 500% locally in the renal vascular wall in dTGR; however, COMT activity in the whole kidney remained unchanged. Urinary dopamine excretion, a marker of renal dopaminergic tone, was decreased by 50% in untreated dTGR. Even though entacapone decreased renal COMT activity by 40%, the renal dopaminergic tone remained unchanged in entacapone-treated dTGR. Conclusion Our findings suggest that entacapone provides protection against Ang II-induced renal damage through antioxidative and anti-inflammatory mechanisms, rather than by COMT inhibition-induced changes in renal dopaminergic tone.

[1]  D. Ganten,et al.  Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. , 2003, The American journal of pathology.

[2]  E. Schiffrin,et al.  Inflammation and vascular hypertrophy induced by angiotensin II: role of NADPH oxidase-derived reactive oxygen species independently of blood pressure elevation? , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[3]  M. Zenke,et al.  Immunosuppressive treatment protects against angiotensin II-induced renal damage. , 2002, The American journal of pathology.

[4]  J. Cracowski,et al.  Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. , 2002, Trends in pharmacological sciences.

[5]  H. Kasai Chemistry-based studies on oxidative DNA damage: formation, repair, and mutagenesis. , 2002, Free radical biology & medicine.

[6]  N. Vaziri,et al.  Enhanced Nitric Oxide Inactivation and Protein Nitration by Reactive Oxygen Species in Renal Insufficiency , 2002, Hypertension.

[7]  R. Carey Renal Dopamine System: Paracrine Regulator of Sodium Homeostasis and Blood Pressure , 2001 .

[8]  P. Liss,et al.  Changing dopaminergic activity through different pathways: consequences for renal sodium excretion, regional blood flow and oxygen tension in the rat. , 2001, Acta physiologica Scandinavica.

[9]  P. Soares-da-Silva,et al.  D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors. , 2001, Kidney international.

[10]  Friedrich C. Luft,et al.  Endothelial Dysfunction and Xanthine Oxidoreductase Activity in Rats With Human Renin and Angiotensinogen Genes , 2001, Hypertension.

[11]  T. Berndt,et al.  Effect of inhibition of MAO and COMT on intrarenal dopamine and serotonin and on renal function. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[12]  D. Sorescu,et al.  Modulation of Protein Kinase Activity and Gene Expression by Reactive Oxygen Species and Their Role in Vascular Physiology and Pathophysiology , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[13]  G. Dibona,et al.  Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. , 2000, Diabetes.

[14]  D. Sorescu,et al.  NAD(P)H oxidase: role in cardiovascular biology and disease. , 2000, Circulation research.

[15]  E. Mervaala,et al.  Down-regulation of renal glutathione synthesis by systemic nitric oxide synthesis inhibition in spontaneously hypertensive rats. , 2000, Biochemical pharmacology.

[16]  D. Ganten,et al.  Blood pressure-independent effects in rats with human renin and angiotensinogen genes. , 2000, Hypertension.

[17]  D. Ganten,et al.  NF-κB Inhibition Ameliorates Angiotensin II–Induced Inflammatory Damage in Rats , 2000 .

[18]  D. Ganten,et al.  NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. , 2000, Hypertension.

[19]  A. Aperia Intrarenal dopamine: a key signal in the interactive regulation of sodium metabolism. , 2000, Annual review of physiology.

[20]  P. Männistö,et al.  Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. , 1999, Pharmacological reviews.

[21]  J. C. Romero,et al.  State-of-the-Art lecture. Role of angiotensin and oxidative stress in essential hypertension. , 1999, Hypertension.

[22]  D. Ganten,et al.  Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes. , 1999, Journal of the American Society of Nephrology : JASN.

[23]  P. Hansell,et al.  Regulation of Dopamine-Induced Natriuresisby the Dopamine-Metabolizing Enzyme Catechol-O-Methyltransferase , 1999, Nephron Experimental Nephrology.

[24]  D. Ganten,et al.  Hypertension-induced end-organ damage : A new transgenic approach to an old problem. , 1999, Hypertension.

[25]  D. Ganten,et al.  Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. , 1999, Hypertension.

[26]  G. Remuzzi,et al.  Pathophysiology of progressive nephropathies. , 1998, The New England journal of medicine.

[27]  R. Felder,et al.  Renal dopamine receptors in health and hypertension. , 1998, Pharmacology & therapeutics.

[28]  P. Greengard,et al.  The renal dopamine system. , 1998, Advances in pharmacology.

[29]  A. Aperia,et al.  Inhibition of COMT induces dopamine-dependent natriuresis and inhibition of proximal tubular Na+,K+-ATPase. , 1997, Kidney international.

[30]  S. Soinila,et al.  Increase of catechol-O-methyltransferase activity in rat brain microglia after intrastriatal infusion of fluorocitrate, a glial toxin , 1997, Neuroscience Letters.

[31]  T. Lotta,et al.  Iron(III)-chelating properties of the novel catechol O-methyltransferase inhibitor entacapone in aqueous solution. , 1997, Journal of pharmaceutical sciences.

[32]  P. Tuomainen,et al.  Optimization of the Hydrolysis of Conjugated L-DOPA, Dopamine and Dihydroxyphenylacetic Acid in Human Urine for Assay by High-Performance Liquid Chromatography with Electrochemical Detection , 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[33]  J. Ménard,et al.  High human renin hypertension in transgenic rats. , 1997, Hypertension.

[34]  J. Morrow,et al.  The isoprostanes. Current knowledge and directions for future research. , 1996, Biochemical pharmacology.

[35]  L. Packer,et al.  Role of ascorbate in protection by nitecapone against cardiac ischemia-reperfusion injury. , 1995, Biochemical pharmacology.

[36]  P. Tuomainen,et al.  Improved assay of reaction products to quantitate catechol-O-methyltransferase activity by high-performance liquid chromatography with electrochemical detection. , 1995, Journal of chromatography. B, Biomedical applications.

[37]  L. Packer,et al.  Nitecapone: a nitric oxide radical scavenger. , 1994, Biochemistry and molecular biology international.

[38]  L. Packer,et al.  Inhibition of NF-kappa B transcription factor by catechol derivatives. , 1994, Biochemistry and molecular biology international.

[39]  L. Packer,et al.  Antioxidant properties of nitecapone (OR-462). , 1992, Free radical biology & medicine.

[40]  D. Ganten,et al.  Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.